PHARMACOLOG I UPPSALA AB |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0874 SEK | -3.74% |
|
-11.36% | +54.42% |
| 04-24 | Perpetua Medical AB Appoints Camilla Lonn as CFO | CI |
| 04-23 | Pharmacolog i Uppsala AB will Change its Ticker to PERP B from PHLOG B | CI |
| Sales 2022 | 10.11M 926K 1.26M | Sales 2023 | 9.94M 910K 1.24M | Capitalization | 3.75M 343K 469K |
|---|---|---|---|---|---|
| Net income 2022 | -19M -1.74M -2.38M | Net income 2023 | -18M -1.65M -2.25M | EV / Sales 2022 | 3.67 x |
| Net cash position 2022 | 10.3M 943K 1.29M | Net cash position 2023 | 5.48M 502K 685K | EV / Sales 2023 | -0.17 x |
| P/E ratio 2022 |
-2.09
x | P/E ratio 2023 |
-0.13
x | Employees | 10 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 49.1% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -4.42% | ||
| 1 week | -13.52% | ||
| Current month | -12.27% | ||
| 1 month | -12.27% | ||
| 3 months | +16.11% | ||
| 6 months | +132.82% | ||
| Current year | +60.42% |
1 week
0.07
0.10
1 month
0.070.12
Current year
0.040.18
1 year
0.021.55
3 years
0.0212.50
5 years
0.0216.65
10 years
0.0244.20
| Managers | Title | Age | Since |
|---|---|---|---|
Hans Erik Dahlin
FOU | Founder | 79 | 07-01-14 |
Lars Gusch
CEO | Chief Executive Officer | 50 | 21-12-31 |
LiseLotte Söder
DFI | Director of Finance/CFO | 60 | 20-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 76 | 16-12-31 | |
Hans Erik Dahlin
FOU | Founder | 79 | 07-01-14 |
Ragnar Linder
BRD | Director/Board Member | 71 | 18-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-29 | 0.0874 | -3.74% | 75 157 |
| 24-04-26 | 0.0908 | -4.42% | 138,200 |
| 24-04-25 | 0.095 | -4.04% | 892,254 |
| 24-04-24 | 0.099 | +2.06% | 49,697 |
| 24-04-23 | 0.097 | -1.62% | 366,694 |
Delayed Quote Nasdaq Stockholm, April 26, 2024 at 10:37 am
More quotes
Perpetua Medical AB (publ), formerly Pharmacolog I Uppsala AB (publ), is a Sweden-based medical technology company that develops systems and solutions which aim to optimize and ensure correct and effective treatment with injectable drugs. The Company provides solutions and products that verifies that drugs and narcotics used in surgery have not been tampered with, its solutions make a vital contribution to preventing drug diversion. Its products Pharmacolog Dashboard offers a variety of valuable tools, generating reports and statistical analyses of validated pharmaceuticals. Another product WasteLog is a device that manages the workflow by instantly analyzing the waste and returns of injectable controlled substances.
Calendar
2024-08-28
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +60.42% | 899K | |
| -12.97% | 19.08B | |
| -46.21% | 2.65B | |
| +18.15% | 1.87B | |
| -3.12% | 1.61B | |
| +22.81% | 1.21B | |
| -10.69% | 1.02B | |
| -20.89% | 905M | |
| -6.77% | 716M | |
| -18.10% | 682M |
- Stock Market
- Equities
- PERP B Stock
